Objective Left ventricular (LV) remodeling following myocardial infarction (MI) is characterized by progressive alterations of structure and function, named LV remodeling. Although several risk factors such as infarct size have been identified, LV remodeling remains difficult to predict in clinical practice. Changes within the extracellular matrix, involving matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), are an integral part of left ventricular (LV) remodeling after myocardial infarction (MI). We investigated the temporal profile of circulating MMPs and TIMPs and their relations with LV remodeling at 1 year and clinical outcome at 3 years in post-MI patients. Methods This prospective multicentre study included 246 patients with a first anterior MI. Serial echocardiographic studies were performed at hospital discharge, 3 months, and 1 year after MI, and analysed at a core laboratory. LV remodeling was defined as the percent change in LV end-diastolic volume (EDV) from baseline to 1 year. Serum samples were obtained at hospital discharge, 1, 3, and 12 months. Multiplex technology was used for analysis of MMP-1, -2, -3, -8, -9, -13, and TIMP-1, -2, -3, -4 serum levels. Results Baseline levels of MMP-8 and MMP-9 were positively associated with changes in LVEDV (P = 0.01 and 0.02, respectively). When adjusted for major baseline characteristics, MMP-8 levels remained an independent predictor LV remodeling (P = 0.025). By univariate analysis, there were positive relations between cardiovascular death or hospitalization for heart failure during the 3-year follow-up and the baseline levels of MMP-2 (P = 0.03), MMP-8 (P = 0.002), and MMP-9 (P = 0.03). By multivariate analysis, MMP-8 was the only MMP remaining significantly associated with clinical outcome (P = 0.02). Conclusion Baseline serum MMP-8 is a significant predictor of LV remodeling and cardiovascular outcome after MI and may help to improve risk stratification.
References
[1]
Pfeffer MA, Braunwald E (1990) Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161–1172.
[2]
St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, et al. (1994) Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 89: 68–75.
[3]
Savoye C, Equine O, Tricot O, Nugue O, Segrestin B, et al. (2006) Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the remodelage ventriculaire [REVE] study group). Am J Cardiol 98: 1144–1149.
[4]
Fertin M, Hennache B, Hamon M, Ennezat PV, Biausque F, et al. (2010) Usefulness of serial assessment of B-type natriuretic peptide, troponin I, and C-reactive protein to predict left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). Am J Cardiol 106: 1410–1416.
[5]
St John Sutton M, Pfeffer MA, Moye L, Plappert T, Rouleau JL, et al. (1997) Cardiovascular death and left ventricular remodeling two years after myocardial infarction: Baseline predictors and impact of long-term use of captopril: Information from the survival and ventricular enlargement (SAVE) trial. Circulation 96: 3294–3299.
[6]
Fertin M, Dubois E, Belliard A, Amouyel P, Pinet F, et al. (2012) Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. Am J Cardiol 110: 277–283.
[7]
Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev 87: 1285–1342.
[8]
Etoh T, Joffs C, Deschamps AM, Davis J, Dowdy K, et al. (2001) Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 281: H987–H994.
[9]
Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, et al. (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063–3070.
[10]
Creemers EE, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, et al. (2003) Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 284: H364–H371.
[11]
Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, et al. (2002) Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-term prognostic implications. Circulation 106: 2351–2357.
[12]
Garcia-Alvarez A, Sitges M, Delgado V, Ortiz J, Vidal B, et al. (2009) Relation of plasma brain natriuretic peptide levels on admission for ST-elevation myocardial infarction to left ventricular end-diastolic volume six months later measured by both echocardiography and cardiac magnetic resonance. Am J Cardiol 104: 878–882.
[13]
Lalu MM, Pasini E, Schulze CJ, Ferrari-Vivaldi M, Ferrari-Vivaldi G, et al. (2005) Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 26: 27–35.
[14]
Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, et al. (2006) Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: Relation to left ventricular remodeling. Circulation 114: 1020–1027.
[15]
Samnegard A, Silveira A, Tornvall P, Hamsten A, Ericsson CG, et al. (2006) Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 259: 530–536.
[16]
Gerlach RF, Meschiari CA, Marcaccini AM, Palei AC, Sandrim VC, et al. (2009) Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. Clin Chem Lab Med 47: 888–891.
[17]
Nilsson L, Hallen J, Atar D, Jonasson L, Swahn E (2012) Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 98: 31–36.
[18]
van den Borne SW, Cleutjens JP, Hanemaaijer R, Creemers EE, Smits JF, et al. (2009) Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 18: 37–43.
[19]
Squire IB, Evans J, Ng LL, Loftus IM, Thomspson MM (2004) Plasma MMP-2 and MMP-9 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10: 328–333.
[20]
Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, et al. (2007) Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: A prospective cohort study. Eur Heart J 28: 711–718.
[21]
Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, et al. (2008) Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: Novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 29: 2116–2124.
[22]
Miyazaki S, Kasai T, Miyauchi K, Miyazaki T, Akimoto Y, et al. (2010) Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circ J 74: 1158–1164.
[23]
Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, et al. (2008) Circulating stromelysin-1 (MMP-3): A novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 10: 133–139.
[24]
Weir RA, Balmain S, Steedman T, Ng LL, Squire IB, et al. (2010) Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction. J Thromb Thrombolysis 29: 421–428.
[25]
Weir RA, Clements S, Steedman T, Dargie HJ, McMurray JJ, et al. (2011) Plasma TIMP-4 predicts left ventricular remodeling after acute myocardial infarction. J Card Fail 17: 465–471.
[26]
Tuomainen AM, Nyyssonen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, et al. (2007) Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 27: 2722–2728.
[27]
Peeters W, Moll FL, Vink A, van der Spek PJ, de Kleijn DP, et al. (2011) Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J 32: 2314–2325.
